FDA has approved Vabysmo® for the treatment of macular edema following retinal vein occlusion.
Roche announced today that the U.S. FDA has approved Vabysmo® (faricimab) for the treatment of macular edema following retinal vein occlusion (RVO). RVO is the third indication for Vabysmo, in addition to neovascular or ‘wet’ age-related macular degeneration (AMD) and…